House
Sign inCreate account
Drug lookup
Drug reference

ceftolozane-tazobactam

Cephalosporin–β-lactamase inhibitor combination · Antibacterial; Cephalosporin/β-Lactamase Inhibitor

Cephalosporin–β-lactamase inhibitor combinationAntibacterial; Cephalosporin/β-Lactamase Inhibitor
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
B
FDA category + note

Mechanism

Ceftolozane inhibits bacterial cell-wall synthesis. Tazobactam inhibits a broader spectrum of β-lactamases, including ESBLs.

Side effects

Common
Gastrointestinal side effects (e.g., diarrhea)
Serious
  • Hypersensitivity reactions (rash to anaphylaxis)
  • Serum sickness
  • Stevens-Johnson syndrome
  • Nephropathy
  • Hematologic reactions (neutropenia, prolonged use)
  • Neurotoxicity (seizure, high doses, renal impairment)

Pregnancy & lactation

Pregnancy

B

Related guidelines

Heart failure in diabetes
RSSDI · Cardiology · 2023
Hypertension in adults
ICMR · Cardiology · 2019
Hypertrophic cardiomyopathy
ESC · Cardiology · 2026
Pulmonary tuberculosis
RNTCP · Infectious Disease · 2023
Dyslipidaemia in diabetes
RSSDI · Endocrinology · 2022

Other Cephalosporin–β-lactamase inhibitor combination drugs

ceftazidime-avibactam
0 brands

Ask House about ceftolozane-tazobactam

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Sources: Harrison 22e·Verified: 2026-05-10 · House clinical team